Detailed Information
Cited 1 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Phase 2 study of tarlatamab, a DLL3-targeting, half life-extended, bispecific T-cell engager (HLE BiTE) immuno-oncology therapy, in relapsed/refractory small cell lung cancer (SCLC).
- Authors
- Ramalingam, SS[Ramalingam, Suresh S.]; Ahn, MJ[Ahn, Myung-Ju]; Akamatsu, H[Akamatsu, Hiroaki]; Blackhall, FH[Blackhall, Fiona Helen]; Borghaei, H[Borghaei, Hossein]; Hummel, HD[Hummel, Horst-Dieter]; Johnson, ML[Johnson, Melissa Lynne]; Reck, M[Reck, Martin]; Zhang, Y[Zhang, Yiran]; Jandial, D[Jandial, Danielle]; Cheng, S[Cheng, Sunfa]; Paz-Ares, LG[Paz-Ares, Luis G.]
- Issue Date
- 1-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.